

CARE*Link Documentation of COVID-19 Vaccination – Updated 5/6/22

This reference sheet is intended to assist with CARE*Link documentation of COVID-19 vaccination administration and should not replace clinical judgement. Please reference CDC’s website for COVID-19 Vaccines: <https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf>.

	Pfizer	Moderna	Janssen	HMT Vaccine Series	Notes
5 – 11 years (includes immuno-compromised)	Dose 1 (10 mcg / 0.2 mL) Dose 2 (10 mcg / 0.2 mL) Dose 3 (10 mcg / 0.2 mL)	Not Approved	Not Approved	<ul style="list-style-type: none"> Pediatric Pfizer 2-dose Pediatric Pfizer 3-dose series for immunocompromised individuals 	<p><i>*See Considerations section below for 11 year-olds turning 12 years old during vaccination series</i></p> <p><i>Interval between 1st and 2nd Pediatric Pfizer dose is 21 days.</i></p> <p><i>Dose 3 only for immunocompromised individuals. Administer 3rd dose 28 days after primary series.</i></p>
12 – 17 years (includes immuno-compromised)	Dose 1 (30 mcg / 0.3 mL) Dose 2 (30 mcg / 0.3 mL) Dose 3 (30 mcg / 0.3 mL) 1 st Booster (30 mcg / 0.3 mL) 2 nd Booster (30 mcg / 0.3 mL)	Not Approved	Not Approved	<ul style="list-style-type: none"> Pfizer 2-dose Pfizer 5-dose series for immunocompromised Individuals 1st booster dose 5 months after primary series 2nd booster dose 4 months after 1st booster 	<p><i>Interval between 1st and 2nd Pfizer dose can be 3-8 weeks if the patient is not immunocompromised. If they are immunocompromised, interval between 1st and 2nd Pfizer dose is 21 days.</i></p> <p><i>Dose 3 only for immunocompromised individuals. Administer 3rd dose 28 days after primary series.</i></p> <p><i>1st Booster dose can be given 5 months after completing primary series. If patient is immunocompromised, 1st booster dose can be given 3 months from 3rd dose.</i></p> <p><i>2nd Booster dose can be given 4 months after the 1st booster for immunocompromised patients.</i></p>
18+ years (not including immuno-compromised)	Dose 1 (30 mcg / 0.3 mL) Dose 2 (30 mcg / 0.3 mL) 1 st Booster (30 mcg / 0.3 mL)	Dose 1 (100 mcg / 0.5 mL) Dose 2 (100 mcg / 0.5 mL) 1 st Booster (50 mcg / 0.25 mL)	Dose 1 (0.5 mL) Booster (0.5 mL)	<ul style="list-style-type: none"> Pfizer/Moderna 2-dose Janssen 1-dose 1st Booster dose after primary series (see notes for timing, which depends on primary series that was given) 	<p><i>Booster may be a different vaccine product than the primary series (“mix and match”)</i></p> <p><i>Interval between 1st and 2nd Pfizer dose is 3-8 weeks. Interval remains at 21 days if patient is above 65 years of age.</i></p> <p><i>Interval between 1st and 2nd Moderna dose is 4-8 weeks. Interval remains at 28 days if patient is above 65 years of age.</i></p>

	2 nd Booster (30 mcg / 0.3 mL)	2 nd Booster (50 mcg / 0.25 mL)		<ul style="list-style-type: none"> 2nd Booster dose 4 months after 1st Booster dose 	<p><i>If Moderna and Pfizer is the primary series, administer 1st booster 5 months after 2nd dose.</i></p> <p><i>If Janssen is the primary series, administer booster after 2 months.</i></p> <p><i>2nd booster of Moderna or Pfizer can be given 4 months after 1st booster for adults ages 50+.</i></p> <p><i>If Janssen was received for the primary series and first booster, a 2nd booster of Moderna or Pfizer can be given 4 months after 1st booster for adults ages 50+.</i></p>
18+ years immuno-compromised	<p>Dose 1 (30 mcg / 0.3 mL)</p> <p>Dose 2 (30 mcg / 0.3 mL)</p> <p>Dose 3 (30 mcg / 0.3 mL)</p> <p>1st Booster (30 mcg / 0.3 mL)</p> <p>2nd Booster (30 mcg / 0.3 mL)</p>	<p>Dose 1 (100 mcg / 0.5 mL)</p> <p>Dose 2 (100 mcg / 0.5 mL)</p> <p>Dose 3 (100 mcg / 0.5 mL)</p> <p>1st Booster (50 mcg / 0.25 mL)</p> <p>2nd Booster (50 mcg / 0.25 mL)</p>	<p>Dose 1 (0.5 mL)</p> <p>Additional dose (0.5 mL)</p> <p>Booster (0.5 mL)</p>	<ul style="list-style-type: none"> Pfizer/Moderna 2-dose Janssen 1-dose 1st Booster dose after primary series Janssen 4-dose series for immunocompromised individuals Pfizer/Moderna 5-dose series for immunocompromised individuals 	<p><i>Booster may be a different vaccine product than the primary series ("mix and match")</i></p> <p><i>Interval between 1st and 2nd Pfizer dose is 21 days.</i></p> <p><i>Interval between 1st and 2nd Moderna dose is 28 days.</i></p> <p><i>If Janssen is the primary series, they should receive an additional dose of Pfizer or Moderna 28 days after 1-dose primary series. Booster dose can be given 2 months after additional dose.</i></p> <p><i>If Janssen is the primary series and they are requesting Moderna as their additional dose, administer a full dose (0.5 mL). 1st booster dose can be subsequently given 2 months after. If they are requesting Moderna again, administer a half dose (0.25 mL). 2nd booster dose can be given 4 months after 1st booster. Total of 4-doses given. *See considerations.</i></p> <p><i>If Pfizer/Moderna is primary series, they can receive a 3rd dose 28 days after 2-dose primary series. 1st Booster dose can be given in 3 months. 2nd Booster dose can be given 4 months after 1st Booster. Total of 5 doses.</i></p>

Considerations

11 year-old turning 12 years old during vaccination series:

- Eligible to receive either Pediatric Pfizer (10 mcg/0.2 mL) or regular dose of Pfizer (30 mcg/0.3 mL) if within 30 days before **AND** after birthdate.
- Verify that birthdate is accurate to ensure patient receives the appropriate vaccine dose.

CDC allows a 4-day grace period prior to the FDA-approved and EUA-authorized vaccination schedule.

Patients are able to “mix-and-match” for their booster dose. The booster dose may be a different vaccine product than the primary series.

1st and 2nd dose interval for Pfizer and Moderna patients extends to 8 weeks unless the patient is immunocompromised or over 65 years of age. For the male population ages 12-39, taking the 2nd primary dose later decreases small risk for myocarditis. Vaccine effectiveness may also increase with increased interval.

If the patient received a Janssen as their primary series and they are immunocompromised, they are recommended to receive an mRNA vaccine as their additional dose 28 days after. If the additional dose requested is Moderna, they would receive a Moderna full dose (0.5 mL). 2 months after, they are able to receive a Moderna booster dose (0.25 mL). If the patient is immunocompromised and had mistakenly received a Moderna booster dose (0.25 mL) as their additional dose, then the CDC allows a Moderna full dose (0.5 mL) to be administered as their booster dose 2 months after. If the patient received two doses of Janssen prior, then they would be eligible for an mRNA vaccine booster. If the mRNA vaccine requested is Moderna, administer a full dose (0.5 mL). A 2nd booster can be received 4 months after first booster.

For more information on the CDC Interim Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

WARNING: THROMBOSIS WITH THROMBOCYTOPENIA SYNDROME See Full EUA Prescribing Information for complete warning. The Janssen COVID-19 Vaccine can cause thrombosis with thrombocytopenia syndrome (TTS) which may be life-threatening. TTS may involve thrombosis at unusual locations for a thrombus (i.e., cerebral vein, visceral artery or vein, extremity artery, central artery or vein) or in an extremity vein or pulmonary artery. Among reported cases of TTS following administration of the Janssen COVID-19 Vaccine, symptoms began approximately one to two weeks after vaccination. Instruct Janssen COVID-19 Vaccine recipients to seek immediate medical attention for shortness of breath, chest pain, leg swelling, persistent abdominal pain, neurological symptoms (including severe or persistent headaches or blurred vision), or petechiae beyond the site of vaccination. The clinical course of TTS following administration of the Janssen COVID-19 Vaccine shares features with autoimmune heparin-induced thrombocytopenia. In individuals with suspected TTS, the use of heparin may be harmful and alternative treatments may be needed. Do not administer the Janssen COVID-19 Vaccine to individuals with a history of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any other adenovirus vectored COVID-19 vaccine.